ctrl-trade
All companies

LLY vs MRK

Eli Lilly and Company and Merck & Co., Inc., side by side.

A close call — LLY edges ahead, two core metrics to two.

LLY is growing far faster (revenue 55.5% vs 4.9%) and keeps far more of every sales dollar (35.0% net vs 13.6%). Both already trade close to their analyst price targets, so there's little easy upside priced in either way. MRK's case rests on a cheaper earnings multiple (P/E 36.3x vs 41.9x), a lighter balance sheet (debt-to-equity 1.07x vs 1.39x), and steadier price action (beta 0.20x vs 0.51x).

LLY leads on

ProfitabilityGrowthReturn on equity

MRK leads on

ValuationBalance sheetLower volatilityDividend
Eli Lilly and Company
LLY Drug Manufacturers - General

Eli Lilly and Company

Data as of July 23, 2026
View full LLY profile →
Merck & Co., Inc.
MRK Drug Manufacturers - General

Merck & Co., Inc.

Data as of July 23, 2026
View full MRK profile →

Figures reflect each company's latest snapshot — no metric is a verdict on its own. New to these numbers? Learn how to read them →

Company Size

How large is this company relative to the overall market?

Metric LLY MRK

Company Size

$1.05T · Mega-cap

$321.19B · Mega-cap

Valuation

Is this stock priced cheaply or expensively relative to its earnings and revenue?

Metric LLY MRK

P/E Ratio

41.9x

36.3x

Forward P/E

26.3x

13.5x

Price-to-Sales

14.5x

4.9x

Profitability

How efficiently does the company turn revenue into profit?

Metric LLY MRK

Profit Margin

35.0%

13.6%

Gross Margin

82.8%

76.7%

Return on Equity

107.5%

18.9%

Growth

Is the business expanding — or contracting?

Metric LLY MRK

Revenue Growth

55.5%

4.9%

Earnings Growth

169.9%

Financial Health

Can the company handle its debts and short-term obligations?

Metric LLY MRK

Debt-to-Equity

1.39x

1.07x

Current Ratio

1.50x

1.30x

Dividends

Does the company pay shareholders regular cash income?

Metric LLY MRK

Dividend Yield

0.5%

2.6%

Risk & Volatility

How much does this stock move relative to the overall market?

Metric LLY MRK

Volatility (Beta)

0.51x

0.20x

Analyst View

What do professional Wall Street analysts say about this stock?

Metric LLY MRK

Analyst Consensus

Buy (27 analysts)

Buy (26 analysts)

Analyst Target Price

$1270.37

+7.8% vs price

$134.04

+3.1% vs price

This comparison is a factual summary of reported metrics, not a recommendation to buy, sell, or hold either stock. One company leading on a metric doesn't make it the better investment for you.

Early access

See the whole picture inside Ctrl-Trade

This page is a free preview. Inside the app, the full fundamentals overview sits right next to your positions — and you can run a complete comparison against any stock, or an entire industry, in a single view.

Not yet public — join the waitlist for early access. No spam.

Full fundamentals, right beside your trades
Compare any two stocks, head to head
Or stack a whole industry side by side